PMID- 33679806
OWN - NLM
STAT- MEDLINE
DCOM- 20210923
LR  - 20210923
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 12
DP  - 2021
TI  - Tolerogenic Immunotherapy: Targeting DC Surface Receptors to Induce 
      Antigen-Specific Tolerance.
PG  - 643240
LID - 10.3389/fimmu.2021.643240 [doi]
LID - 643240
AB  - Dendritic cells (DCs) are well-established as major players in the regulation of 
      immune responses. They either induce inflammatory or tolerogenic responses, 
      depending on the DC-subtype and stimuli they receive from the local environment. 
      This dual capacity of DCs has raised therapeutic interest for their use to modify 
      immune-activation via the generation of tolerogenic DCs (tolDCs). Several 
      compounds such as vitamin D3, retinoic acid, dexamethasone, or IL-10 and TGF-beta 
      have shown potency in the induction of tolDCs. However, an increasing interest 
      exists in defining tolerance inducing receptors on DCs for new targeting 
      strategies aimed to develop tolerance inducing immunotherapies, on which we focus 
      particular in this review. Ligation of specific cell surface molecules on DCs can 
      result in antigen presentation to T cells in the presence of inhibitory 
      costimulatory molecules and tolerogenic cytokines, giving rise to regulatory T 
      cells. The combination of factors such as antigen structure and conformation, 
      delivery method, and receptor specificity is of paramount importance. During the 
      last decades, research provided many tools that can specifically target various 
      receptors on DCs to induce a tolerogenic phenotype. Based on advances in the 
      knowledge of pathogen recognition receptor expression profiles in human DC 
      subsets, the most promising cell surface receptors that are currently being 
      explored as possible targets for the induction of tolerance in DCs will be 
      discussed. We also review the different strategies that are being tested to 
      target DC receptors such as antigen-carbohydrate conjugates, antibody-antigen 
      fusion proteins and antigen-adjuvant conjugates.
CI  - Copyright (c) 2021 Castenmiller, Keumatio-Doungtsop, van Ree, de Jong and van 
      Kooyk.
FAU - Castenmiller, Charlotte
AU  - Castenmiller C
AD  - Department of Experimental Immunology, Amsterdam University Medical Centers, 
      Amsterdam Institute for Infection & Immunity, University of Amsterdam, Amsterdam, 
      Netherlands.
FAU - Keumatio-Doungtsop, Brigitte-Carole
AU  - Keumatio-Doungtsop BC
AD  - Department of Molecular Cell Biology and Immunology, Amsterdam University Medical 
      Centers, Amsterdam Institute for Infection & Immunity, Vrije Universiteit 
      Amsterdam, Amsterdam, Netherlands.
FAU - van Ree, Ronald
AU  - van Ree R
AD  - Department of Experimental Immunology, Amsterdam University Medical Centers, 
      Amsterdam Institute for Infection & Immunity, University of Amsterdam, Amsterdam, 
      Netherlands.
AD  - Department of Otorhinolaryngology, Amsterdam University Medical Centers, 
      University of Amsterdam, Amsterdam, Netherlands.
FAU - de Jong, Esther C
AU  - de Jong EC
AD  - Department of Experimental Immunology, Amsterdam University Medical Centers, 
      Amsterdam Institute for Infection & Immunity, University of Amsterdam, Amsterdam, 
      Netherlands.
FAU - van Kooyk, Yvette
AU  - van Kooyk Y
AD  - Department of Molecular Cell Biology and Immunology, Amsterdam University Medical 
      Centers, Amsterdam Institute for Infection & Immunity, Vrije Universiteit 
      Amsterdam, Amsterdam, Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20210219
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (IL10 protein, human)
RN  - 0 (Receptors, Cell Surface)
RN  - 0 (Transforming Growth Factor beta)
RN  - 130068-27-8 (Interleukin-10)
SB  - IM
MH  - *Antigen Presentation
MH  - Dendritic Cells/*immunology
MH  - Humans
MH  - *Immune Tolerance
MH  - *Immunotherapy
MH  - Interleukin-10/immunology
MH  - Receptors, Cell Surface/*immunology
MH  - T-Lymphocytes, Regulatory/*immunology
MH  - Transforming Growth Factor beta/immunology
PMC - PMC7933040
OTO - NOTNLM
OT  - C-type lectins
OT  - Siglecs
OT  - allergy
OT  - auto immune diseases
OT  - dendritic cell
OT  - immunotherapy
OT  - surface receptors
OT  - tolerance
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/03/09 06:00
MHDA- 2021/09/24 06:00
PMCR- 2021/01/01
CRDT- 2021/03/08 05:50
PHST- 2020/12/17 00:00 [received]
PHST- 2021/02/02 00:00 [accepted]
PHST- 2021/03/08 05:50 [entrez]
PHST- 2021/03/09 06:00 [pubmed]
PHST- 2021/09/24 06:00 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2021.643240 [doi]
PST - epublish
SO  - Front Immunol. 2021 Feb 19;12:643240. doi: 10.3389/fimmu.2021.643240. eCollection 
      2021.